ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Valuation Check After Strong Phase 3 Amlitelimab Results In Atopic Dermatitis
Sanofi (ENXTPA:SAN) is back in focus after reporting Phase 3 data for amlitelimab in atopic dermatitis, as the SHORE and COAST 2 trials met key efficacy goals and the company outlined plans for global regulatory filings.
See our latest analysis for Sanofi.
The amlitelimab update lands after an eventful few months for Sanofi, including EU approval for Teizeild in type 1 diabetes, new China approvals for Myqorzo and Redemplo, and the completed $2.2b Dynavax acquisition. However, the 90 day...